Aspira Women’s Health Addresses Clinical Disparities in Ovarian Cancer Risk Assessment with OVA1plus Across Racial Profiles Aspira Women’s Health provides physicians with innovative risk assessment tools that are not discriminatory, for all women.
Digital Asset Direct
by
Aspira Women's Health Inc.
Austin, Texas
|
October 28, 2020 08:00 AM Eastern Daylight Time
Detecting ovarian cancer in Black women presents physicians with many challenges, as testing is less sensitive in that population. Aspira Women’s Health is evolving and improving risk detection, bridging the gap between current disparities that exist in ovarian cancer detection. OVA1plus, a reflex process combining OVA1 and Overa is a multivariate biomarker approach for assessing Ovarian Cancer risk in women with a pelvic mass with a higher sensitivity across all ethnicities.
Contact Details
Jaime Abrusci
+1 646-599-8606
Company Website
